Targeting glycolysis and downstream reactions by these MJ derivative HK-II inhibitors can potentially lead to a superior cell killing effect via including different cell death mechanisms in highly heterogenic and drug-resistant tumors such as GBM. The gene discussed is HK2; the disease is glioblastoma.